Latest Options News

Ridley Corporation has completed its $300 million acquisition of Incitec Pivot Fertilisers, marking a strategic expansion into a new growth pillar within Australian agricultural services.

Rumble Resources is set to begin a 20,000-metre diamond drilling program at its Western Queen Gold Project, aiming to expand gold resources and explore tungsten revenue potential as it advances underground mining studies.

Infinity Metals has submitted key documentation for its San José Lithium Project mining licence in Spain, moving closer to public consultation despite delays. The company also announces executive role changes to streamline costs amid a softer lithium market.

G50 Corp has completed the acquisition of 100% ownership of its Golconda Project in Arizona, following significant exploration successes that position the company for accelerated development and commercialisation.

Australian Mines Limited has raised $4 million through a strongly supported placement, enabling expanded drilling at its premium Flemington Scandium and Boa Vista Gold projects.

EVE Health Group has reached a pivotal milestone with the first patient prescriptions of Dyspro™, its cannabinoid-based treatment for dysmenorrhoea and endometriosis, alongside launching an educational platform to support patients and clinicians.

St Barbara updates shareholders on its ongoing strategic review, highlighting stalled Atlantic separation talks and advancing Simberi sale discussions, while reaffirming commitment to a major expansion.

Delorean Corporation has released its audited 2025 Annual Report, revealing key adjustments from its preliminary results including lower revenue, increased tax expenses, and a significant reclassification of borrowings.

Quantum Graphite Ltd reported a significant revenue jump alongside a $4.9 million net loss for FY2025, as it pushes forward with its Uley 2 graphite project backed by major infrastructure and funding initiatives.

EMVision Medical Devices has launched a Share Purchase Plan allowing shareholders to invest up to A$30,000 at $1.94 per share, sweetened by free-attaching options exercisable at $3.40 each.

Ryzon Materials has expanded its engineering contract with Xinhai to fast track production at its Nachu Graphite Project, alongside a $500,000 capital raising from Xinhai. The deal involves a $3.5 million contract largely settled through shares and options, pending shareholder approval.

Paradigm Biopharmaceuticals has dosed participants in its pivotal Phase 3 trial for knee osteoarthritis across the US and Australia, progressing steadily towards a mid-2026 interim analysis.